甲泼尼龙琥珀酸钠联合注射用氨溴索治疗喘息性支气管肺炎的临床疗效

Clinical Efficacy of Methylprednisolone Sodium Succinate Combined with Ambroxol for Injection in the Treatment of Asthmatic Bronchial Pneumonia

目的研究甲泼尼龙琥珀酸钠联合注射用氨溴索治疗喘息性支气管肺炎的临床疗效。方法以2021年5月-2023年5月信丰县妇幼保健院收治的60例喘息性支气管肺炎患者为研究对象,依据随机数字表法分为对照组(30例)与观察组(30例)。对照组给予甲泼尼龙琥珀酸钠治疗,观察组则在其基础上联合注射用氨溴索治疗,比较两组临床疗效、症状缓解时间(喘息、咳嗽、气促、哮鸣音)、生化指标[白细胞(WBC)、C反应蛋白(CRP)]、肺功能[第1 s用力呼气容积(FEV_(1))、用力肺活量(FVC)、FEV_(1)/FVC]、不良反应。结果观察组总有效率高于对照组(P<0.05)。观察组症状缓解时间(喘息、咳嗽、气促、哮鸣音)短于对照组(P<0.05)。两组治疗后WBC、CRP水平低于治疗前,且观察组WBC、CRP水平低于对照组(P<0.05)。两组治疗后FEV_(1)、FVC、FEV_(1)/FVC高于治疗前,且观察组FEV_(1)、FVC、FEV_(1)/FVC高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论甲泼尼龙琥珀酸钠联合注射用氨溴索治疗喘息性支气管肺炎疗效肯定,可加快症状缓解,下调炎症指标,促进肺功能恢复,具有较高的安全性。

Objective To study the clinical efficacy of methylprednisolone sodium succinate combined with ambroxol for injection in the treatment of asthmatic bronchopneumonia.Methods A total of 60 patients with asthmatic bronchopneumonia admitted to Xinfeng County Maternal and Child Health Hospital from May 2021 to May 2023 were divided into control group(30 patients)and observation group(30 patients)according to random number table method.The control group was treated with methylprednisolone sodium succinate,while the observation group was treated with ambroxol for injection on the basis of the control group.The clinical efficacy,symptom relief time(wheezing,cough,panting,wheezing sound),biochemical indexes[white blood cell(WBC),C-reactive protein(CRP)],lung function[forced expiratory volume in the first second(FEV_(1)),forced vital capacity(FVC),FEV_(1)/FVC]and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).The symptom relief time(wheezing,cough,panting,wheezing sound)in the observation group was shorter than that in the control group(P<0.05).The levels of WBC and CRP in the two groups after treatment were lower than those before treatment,and the levels of WBC and CRP in the observation group were lower than those in the control group(P<0.05).After treatment,FEV_(1),FVC and FEV_(1)/FVC in the two groups were higher than those before treatment,and FEV_(1),FVC and FEV_(1)/FVC in the observation group were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Methylprednisolone sodium succinate combined with ambroxol for injection is effective in the treatment of asthmatic bronchopneumonia,which can accelerate the relief of symptoms,down-regulate inflammatory indicators,promote the recovery of lung function,and has high safety.